Filip Janku,
Associate Professor, Center Medical Director, Clinical and Translational Research Center,
The University of Texas MD Anderson Cancer Center
Filip Janku, MD, PhD is Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Dr. Janku received his MD and PhD degrees from the Charles University, Prague, Czech Republic. Dr. Janku is principal investigator for numerous phase I trials, most of which involve novel, targeted agents, some of those being first-in-human studies. Dr. Janku received multiple awards for his research efforts, including four Merit Awards from ASCO as well as an American Association for Cancer Research Scholar-in-Training Award.
Liquid Biopsies in the Era of Precision Medicine
Thursday, 15 January 2015 at 15:00
Add to Calendar ▼2015-01-15 15:00:002015-01-15 16:00:00Europe/LondonLiquid Biopsies in the Era of Precision MedicinePrognostic, Predictive, and POC: Biomarkers from Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Molecular profiling is usually performed on DNA from archival tumor samples obtained during routine therapeutic or diagnostic procedures, which do not necessarily reflect the fact that the molecular profile might change over time. The plasticity of molecular profiles includes emergence of secondary molecular aberrations, which can ultimately drive resistance to treatment. To detect such changes new techniques capable of monitoring molecular profile in the real time need to be implemented. Since sequential or multiple biopsies can hardly be used in routine clinical care because of logistical, financial and ethical barriers there is an unmet for developing new, noninvasive techniques for garnering the greatest amount of information at multiple time points from the least amount of available biologic material. Cell-free (cf) DNA is released to the circulation from cells undergoing apoptosis, necroptosis and active secretion and can be isolated from plasma, serum or urine samples of patients with advanced cancers. In addition, unlike tissue biopsies, obtaining samples of cfDNA (liquid biopsies) is a noninvasive approach, which can be used at multiple time points, with less risk to patients at a lower cost. Molecular profiling of cfDNA offers an attractive approach for molecular diagnosis, monitoring of treatment effects and detection of molecular mechanisms of resistance.
Add to Calendar ▼2015-01-15 00:00:002015-01-16 00:00:00Europe/LondonPrognostic, Predictive, and POC: Biomarkers from Research to ClinicPrognostic, Predictive, and POC: Biomarkers from Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2015-01-15 15:00:002015-01-15 16:00:00Europe/LondonLiquid Biopsies in the Era of Precision MedicinePrognostic, Predictive, and POC: Biomarkers from Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
